Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14121100 | 1.00 | PDE2A (0.43) | PDE2AHTR2AHTR2CHTR2BCES2 | |
| SCHEMBL14121399 | 1.00 | PDE2A (0.43) | PDE2AHTR2AHTR2CHTR2BCES2 | |
| SCHEMBL6816690 | 0.85 | PDE2A (0.47) | PDE2AHTR2AHTR2CHTR2BCES2 | |
| SCHEMBL12868145 | 0.84 | PDE2A (0.46) | PDE2AHTR2AHTR2CHTR2BCES2 | |
| SCHEMBL23675536 | 0.81 | PDE2A (0.61) | PDE2AHTR2AHTR2CHTR2BCES2 | |
| SCHEMBL21801027 | 0.81 | PDE2A (0.51) | PDE2AHTR2AHTR2CHTR2BSCN10A | |
| SCHEMBL22717043 | 0.81 | PDE2A (0.61) | PDE2AHTR2AHTR2CHTR2BCES2 | |
| SCHEMBL20832010 | 0.81 | IDO1 (0.40) | PDE2AHTR2AHTR2CIDO1SLC6A4 | |
| SCHEMBL22717245 | 0.81 | P2RX7 (0.47) | PDE2AHTR2AHTR2CHTR2BCES2 | |
| SCHEMBL19750893 | 0.81 | PDE2A (0.47) | PDE2AHTR2AHTR2CHTR2BCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805141-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | PDE2A 112/4885HTR2A 389/4885HTR2C 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.